Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in Castration-Resistant Prostate Cancer

ABSTRACT: Illumina gene array analyses of prostate cancer cell lines that had acquired resistance to Enzalutamide (MDV3100). mRNA analyses of four cell lines (CWR-R1, LAPC-4, LNCaP, and VCAP) cells that were either untreated, treated for 48hrs with Enz (short-term), or continuously grown in Enzalutamide for >6 months.

ORGANISM(S): Homo sapiens

SUBMITTER: Donald Vander Griend 

PROVIDER: E-GEOD-78201 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress